Hormone therapy: friend or foe? Navigating the benefits and risks for menopausal women

Menopausal hormone therapy (HT) has a complex history, with its usage significantly declining after studies like the Women’s Health Initiative (WHI) revealed increased cardiovascular risks associated with combined estrogen-progestin treatments. Despite these concerns, current research has provided a more nuanced understanding of HT, particularly regarding the timing of initiation, type of hormone, and route of administration.

Recent guidelines from leading medical societies now recommend HT for managing bothersome menopausal symptoms in specific patient groups. These guidelines emphasize the importance of initiating HT in younger women, particularly those within ten years of menopause onset, where the benefits of symptom relief often outweigh the cardiovascular risks. The “timing hypothesis” suggests that initiating HT closer to the onset of menopause can mitigate cardiovascular risks that were previously associated with HT use.

Different forms of HT, including systemic and local therapies, are available, with each offering varying degrees of efficacy and risk. For instance, transdermal estrogen is associated with a lower risk of venous thromboembolism compared to oral formulations, making it a preferred option for women at risk of clotting disorders. Despite the advantages, HT remains contraindicated for women with certain cardiovascular conditions, such as a history of stroke or coronary heart disease, and should be used cautiously in those with other chronic conditions like obesity or diabetes.

As our understanding of HT evolves, it becomes increasingly important to personalize treatment plans, weighing the benefits of symptom relief against the potential risks, particularly in women with preexisting cardiovascular conditions.